1. Introduction
===============

Memory T cells play an important part of the adaptive immune response to infection \[[@B1-viruses-06-00709],[@B2-viruses-06-00709],[@B3-viruses-06-00709]\]. Upon antigen encounter, naïve T cells undergo proliferation and differentiation into different memory T cell subsets which culminate into terminally differentiated effector T cells \[[@B4-viruses-06-00709],[@B5-viruses-06-00709]\]. During the process of maturation, T cells progressively acquire effector functions but also lose the capacity for self-renewal and survival \[[@B1-viruses-06-00709]\]. A small proportion of memory T cells survives the contraction phase and become long-lived memory T cells which have the ability to rapidly acquire effector functions upon reinfection \[[@B3-viruses-06-00709],[@B4-viruses-06-00709]\].

Memory CD4^+^ T cells have conventionally been divided into central memory (CM) and effector memory (EM) based on their surface receptor expression (CCR7, CD62L) and the level and type of cytokine secretion (IFN-γ, IL-2, IL-4) \[[@B6-viruses-06-00709],[@B7-viruses-06-00709]\]. CM CD4^+^ T cells are relatively long-lived memory cells which are able to undergo differentiation into a shorter lived EM T cells upon antigen stimulation \[[@B1-viruses-06-00709],[@B5-viruses-06-00709],[@B7-viruses-06-00709]\] and, although to a lesser extent, in response homeostatic cytokines (for example IL-7 and IL-15) \[[@B8-viruses-06-00709],[@B9-viruses-06-00709]\]. Transitional memory (TM) CD4^+^ T cells have functional and transcriptional characteristics which are in between those of CM and EM T cells \[[@B10-viruses-06-00709]\] and can be distinguished through the additional use of CD27 surface receptor expression \[[@B8-viruses-06-00709]\]. More recently a novel T cell subset, stem memory T cells (TSCM) has been detected in both CD4^+^ and CD8^+^ T cell populations in humans and nonhuman primates \[[@B11-viruses-06-00709],[@B12-viruses-06-00709]\].

This novel T cell subset comprises ^\~^2%--3% of the CD4^+^ and CD8^+^ T cell population in healthy individuals, and exhibits a gene profile between naïve and CM T cells \[[@B11-viruses-06-00709],[@B12-viruses-06-00709]\]. These cells constitute a small proportion of the memory T cell subset and display stem cell-like properties, representing the earliest and longest lasting developmental stage of memory T cells \[[@B12-viruses-06-00709]\]. TSCM cells display common surface markers characteristic of naïve T cells (CD45RA^+^, CD45RO^−^, CCR7^+^, CD27^+^), but can be distinguished from naïve T cells by high expression of CD95 and CD122 (IL-2Rβ) on their cellular surface, markers which are also expressed by memory T cell subsets \[[@B11-viruses-06-00709]\]. TSCM are antigen‑experienced and upon TCR stimulation, exhibit effector activity and are able to differentiate into CM and EM subsets. They have the ability to self-renew in the presence of IL-15 homeostatic signals, and are able to survive for longer periods than CM or EM populations \[[@B12-viruses-06-00709]\].

Previous studies have demonstrated the importance of memory T cells in immune responses to viral infections \[[@B2-viruses-06-00709],[@B13-viruses-06-00709]\]. In HIV-1, CD4^+^ T cells are a key target of infection, where depletion of these cells results in deterioration of the immune system and progression to AIDS \[[@B14-viruses-06-00709],[@B15-viruses-06-00709]\]. Importantly, both CM and TM CD4^+^ T cell subsets have been demonstrated as major HIV-1 cellular reservoirs where the maintenance of these reservoirs is associated with T cell survival and homeostatic proliferation (antigen-driven and IL-7-mediated, respectively) \[[@B8-viruses-06-00709]\]. Additionally, the TSCM subset has been demonstrated to support long-lived T cell memory, with the potential to be a cellular reservoir of HIV‑1 \[[@B12-viruses-06-00709],[@B16-viruses-06-00709],[@B17-viruses-06-00709]\].

Preliminary studies have demonstrated promising results for TSCM with a particular interest in the role of these cells in cancer and HIV-1. In mouse models, TSCM have exhibited increased anti-tumor activity and are being considered for adoptive T cell therapies for cancer patients \[[@B1-viruses-06-00709],[@B12-viruses-06-00709],[@B18-viruses-06-00709]\]. Importantly for HIV-1 research, recent studies \[[@B17-viruses-06-00709]\] have demonstrated CD4^+^ TSCM to contain high per-cell levels of HIV-1 DNA and contribute to the total CD4^+^ T cell reservoir. Thus, long-lived TSCM have the potential to promote HIV-1 viral persistence \[[@B17-viruses-06-00709],[@B19-viruses-06-00709]\].

The cellular tropism of HIV-1 can influence the size and composition of the viral reservoir, with particular CD4^+^ T cell subsets described as cellular reservoirs for HIV-1 \[[@B8-viruses-06-00709],[@B20-viruses-06-00709]\]. How the cellular tropism of HIV-1 for different T cell subtypes alters during disease pathogenesis is largely unknown. Thus, the development of an assay system which has the ability to detect changes in HIV-1 tropism for T cells during disease pathogenesis, and also characterizes changes in tropism between CCR5- and CXCR4-using viruses is important for the design of new therapeutic targets and for characterizing the cellular reservoir of HIV-1.

2. Results and Discussion
=========================

2.1. Development and Validation of a T Cell Assay for the Detection of Infected TSCM
------------------------------------------------------------------------------------

We previously developed an assay to quantify HIV-1 infection in non-TSCM CD4^+^ T cell subsets *in vitro* \[[@B21-viruses-06-00709]\]. This assay detected and quantified HIV-1 infection in CM, TM, EM, naïve and effector memory RA (EMRA) CD4^+^ T cells \[[@B21-viruses-06-00709]\]. In this previous system the CD4^+^ T cells were activated with anti-CD3 and anti-CD28 (5 μg/mL) prior to infection with Env-pseudotyped GFP reporter viruses. The CD4^+^ T cells were cultured in media supplemented with IL-2 (20 U/mL) at all stages of the experiment (described in \[[@B21-viruses-06-00709]\]). Since the recent description of TSCM cells, we have developed a new assay system which incorporates quantitation of HIV-1 infection in the TSCM subset.

TSCM cells are the least differentiated of the memory T cell populations \[[@B11-viruses-06-00709]\]. They express many naïve markers and are relatively rare, comprising approximately 2%--4% of the total CD4^+^ T cells in the blood \[[@B11-viruses-06-00709]\]. They can be differentiated from naïve T cells by the use of the memory marker CD95 and CD122 \[[@B11-viruses-06-00709]\]. In developing the new assay, we first ensured detection of all CD4^+^ T cell subsets in uninfected CD4^+^ T cells from peripheral blood using a panel of cytometry antibodies ([Table 1](#viruses-06-00709-t001){ref-type="table"}, [Figure 1](#viruses-06-00709-f001){ref-type="fig"}).

viruses-06-00709-t001_Table 1

###### 

Flow cytometry panel for the detection of CD4^+^ T cell subsets.

  Cellular Marker    Fluorochrome
  ------------------ ----------------------
  CD4                FITC
  CD122              EF710 (PerCPCy5.5)
  CCR7               AF-647
  CD3                APCCy7
  CD45RO             EF450 (Pacific Blue)
  Viability Dye \*   EF506 (Amcyan)
  CD95               PE-CF594
  CD27 \^            PE-Cy7
  CCR5 ^\#^          PE
  CXCR4 ^\#^         PECy5

\* A fixable viability dye was chosen so the HIV-1 infected cells would also be fixed. \^ CD27 has been chosen over CD62L as expression of CD62L is not reliable on cryopreserved cells \[[@B22-viruses-06-00709]\]. ^\#^ CCR5 and CXCR4 antibodies used for HIV-1 infected samples.

Because TSCM share cellular markers with naïve T cells and are a relatively rare population, we proposed that the activation of CD4^+^ T cells prior to infection in our *in vitro* system may not accurately depict HIV-1 infection of this subset. Therefore, to examine the effect of stimulating CD4^+^ T cells prior to infection and the effect of the addition of IL-2 to the assay, we performed experiments with both stimulated (plates coated with anti-CD3 and anti-CD28) and unstimulated cells in the presence and absence of IL-2 ([Figure 2](#viruses-06-00709-f002){ref-type="fig"}). As expected, without anti-CD3 and anti-CD28 stimulation, and without the addition of IL-2, there was lower T cell infectivity ([Figure 2](#viruses-06-00709-f002){ref-type="fig"}A), however there was also a slight increase in the detection of HIV-1 infected TSCM ([Figure 2](#viruses-06-00709-f002){ref-type="fig"}C). There was little change in the proportion of CD4^+^ T cell subsets infected with or without prior stimulation or the addition of IL-2 ([Figure 2](#viruses-06-00709-f002){ref-type="fig"}B), thus we chose not to stimulate the CD4^+^ T cells in future experiments.

We next performed time course experiments to determine the optimal time to infect the CD4^+^ T cells after isolation. We examined cell viability, infection levels and consistency of T cell subsets infected ([Figure 3](#viruses-06-00709-f003){ref-type="fig"}). These assays confirmed good viability, reproducible infection levels and the greatest consistency with infection of CD4^+^ T cell subsets when infection was on the same day of isolation (day 0) or 24 hours post isolation (day 1, [Figure 3](#viruses-06-00709-f003){ref-type="fig"}A,C--E). We also ensured T cell subset proportions of no virus control wells represented CD4^+^ T cell subset starting populations ([Figure 3](#viruses-06-00709-f003){ref-type="fig"}B). In all conditions the susceptibility of each T cell subset to infection remained consistent. CM cells were the most susceptible to infection by JR-CSF followed by TM, EM, naïve, TSCM and EMRA cells ([Figure 3](#viruses-06-00709-f003){ref-type="fig"}F). Due to the short assay duration (72 hours) and the choice of flow cytometry antibodies for detection of TSCM including CD122 (IL-2Rβ, [Table 1](#viruses-06-00709-t001){ref-type="table"}), we chose not to add IL-2 to the assay at any stage and chose to infect the CD4^+^ T cells one hour post-isolation for the experimental protocol.

![Strategy for identifying CD4^+^ T cell subsets. PBMC were stained with a panel of flow cytometry antibodies for the detection of CD4^+^ T cell subsets. PBMC were first gated on (**A**) FSC *vs*. SSC and then (**B**) viability of CD3^+^ T cells (CD3 *vs*. Viability dye). (**C**) Viable CD3^+^ T cells were gated on CD4^+^ positivity to determine viable CD3^+^CD4^+^ T cells. (**D**) CD3^+^CD4^+^ T cells were gated on CD45RO expression (CD45RO *vs*. CD3) and divided into CD45RO positive and negative cells. Each population, CD45RO positive and negative, was then plotted CCR7 *vs*. CD27 to define each T cell subset. (**E**) CD45RO negative cells were divided into naïve (CD45RO^−^CCR7^+^CD27^+^) and effector (EMRA; CD45ROCCR7^+^CD27^−^) CD4^+^ T cells. (**F**) Cells in the naïve CD4^+^ T cell gate were further divided into TSCM cells using CD122 and CD95 (CD45RO^−^CCR7^+^CD27^+^CD122^+^CD95^+^) (**G**) CD45RO positive cells were divided into transitional memory (TM; CD45RO^+^CCR7^−^CD27^+^), central memory (CM; CD45RO^+^CCR7^+^CD27^+^) and effector memory (EM; CD45RO^+^CCR7^−^CD27^−^) CD4^+^ T cells. This gating strategy allowed EM to be distinguished from TM, similar to methods used by other investigators \[[@B8-viruses-06-00709]\] and as we have described previously \[[@B21-viruses-06-00709]\]. The use of an additional cellular marker, CD27, also enabled better enumeration of T cell subsets, as described previously \[[@B23-viruses-06-00709],[@B24-viruses-06-00709]\]. TSCM were identified using methods similar to those described previously \[[@B11-viruses-06-00709]\]. Percentages represent the percent of the parent population gated (for example, in plot **D**, CD45RO^−^ cells represent 50% of the CD3^+^CD4^+^ T cells gated in plot **C**).](viruses-06-00709-g001){#viruses-06-00709-f001}

![Establishment and optimization of assay conditions for the detection of HIV-1 infected TSCM cells. CD4^+^ T cells were isolated from two donors and infected with 3,000 IU of JR-CSF Env-pseudotyped GFP reporter virus. Cells were incubated for three days prior to infection on coated (anti-CD3 and anti-CD28, 5 μg/mL) or uncoated wells with and without the addition of IL-2 (20 U/mL) to the culture media. A third condition of the addition of IL-2 post-infection (day 3) was also tested. For all conditions, \>1 million events were collected on a LSR Fortessa flow cytometer 3 days post infection. (**A**) There was little change in the level of infection between the assay conditions, although there was a slight reduction in infection in uncoated wells and in wells without IL-2. (**B**) There was little difference in the proportion of CD4^+^ T cell subset infection between the conditions; however, (**C**) there was a trend for an increased infection of TSCM from uncoated wells. Panel **C** represents the naïve, TSCM and EMRA T cell subset populations from panel **B** plotted on a smaller scale. Bar graphs represent the median and range.](viruses-06-00709-g002){#viruses-06-00709-f002}

![Optimization of the detection of infected CD4^+^ T cell subsets over time. CD4^+^ T cells from two donors were infected with 3,000 IU of JR-CSF Env-pseudotyped GFP reporter virus at day 0 (1 hour post isolation), day 1 (24 hours post isolation), day 2 (48 hours post isolation) and day 3 (72 hours post isolation). For all conditions, over 1 million events were collected on a LSR Fortessa 3 days post infection. (**A**) CD4^+^ T cells maintained a good level of viability (\>95% viable) in experimental conditions day 0 and day 1. Viability was measured at the end of the experiment. (**B**) CD4^+^ T cell subset proportions were maintained in no virus control wells (assessed at the end of the experiment) and were similar to freshly isolated CD4^+^ T cells (isolation) at all conditions examined. (**C**) There was a trend for better consistency in the percentage of CD4^+^ T cells infected in wells without the addition of IL-2, and there was a tendency for a higher level of infection at earlier time points. There was little difference in proportion of T cell subsets infected when cells were (**D**) untreated or (**E**) treated with IL-2 post-infection. (**E**) There was a tendency for better consistency of subsets infected at earlier time points. (**F**) A representative pie chart displaying the proportion of CD4^+^ T cell subsets infected (using the condition of cells infected on day 0, without IL-2). Bar graphs represent the median and range.](viruses-06-00709-g003){#viruses-06-00709-f003}

2.2. HIV-1 Infection in CD4^+^ T Cell Subsets by CCR5- and CXCR4-Using Viruses
------------------------------------------------------------------------------

We next confirmed that we could detect and measure HIV-1 infection of the CD4^+^ T cell subsets by both CCR5- and CXCR4-using viruses. The strategy for detecting HIV-1 infection in the different T cell subsets is illustrated in [Figure 4](#viruses-06-00709-f004){ref-type="fig"}. We used the well characterized JR-CSF (CCR5-using) and HXB2 (CXCR4-using) Envs to produce Env-pseudotyped GFP reporter viruses, to examine CD4^+^ T cell subset tropism and infectivity. JR-CSF and HXB2 are frequently used as controls in HIV-1 experiments. Both viruses are derived from patient isolates and are subtype B HIV-1. JR-CSF and HXB2 have been demonstrated to be T cell tropic \[[@B21-viruses-06-00709],[@B25-viruses-06-00709],[@B26-viruses-06-00709]\].

Prior to infection we examined the level of CCR5 and CXCR4 expression on all CD4^+^ T cell subsets from five healthy donors. CD4 expression from the five donors was similar across all T cell subsets (as previously reported \[[@B21-viruses-06-00709]\], and data not shown). CCR5 expression varied between T cell subsets with the highest expression on EM and TM cells (17 +/− 5% and 14 +/− 6%, respectively), a moderate expression on CM cells (9 +/− 5%), lower expression on TSCM (6 +/− 5%) and very low expression on naïve and EMRA (both 1 +/−1 %). CXCR4 expression was high on all T cell subsets (\>70%) with the highest expression on naïve T cells (90 +/− 5%). The distribution of CD4, CCR5 and CXCR4 expression across the T cell subsets was similar to that reported previously for peripheral blood CD4^+^ T cell subsets \[[@B21-viruses-06-00709],[@B27-viruses-06-00709],[@B28-viruses-06-00709],[@B29-viruses-06-00709]\].

CD4^+^ T cells from the five donors were infected with JR-CSF and HXB2 Env-pseudotyped GFP reporter viruses, and showed a similar level of overall infection ranging from 1 to 2% of total CD4^+^ T cells (JR-CSF mean 1.8 +/− 0.8% and HXB2 mean 1.0 +/− 0.3%). There was a difference in CD4^+^ T cell subset tropism between JR-CSF and HXB2, likely due to their difference in use of co-receptor for viral entry ([Figure 5](#viruses-06-00709-f005){ref-type="fig"}). The CCR5-using JR-CSF preferentially infected memory T cell subsets, in particular CM (mean 26.60 +/− 6.23%) and TM (mean 20.00 +/− 7.84%) with a lower level of infection for naïve T cells (mean 12.00 +/− 5.52%, [Figure 5](#viruses-06-00709-f005){ref-type="fig"}A). In contrast, the CXCR4-using HXB2 preferentially infected naïve T cells (mean 25.13 +/− 2.00%) with a lower level of infection in memory T cell subsets (CM mean 13.11 +/− 2.85%, TM mean 12.35 +/− 2.57%, [Figure 5](#viruses-06-00709-f005){ref-type="fig"}A). Both JR-CSF and HXB2 were able to infect a similar proportion of TSCM cells (JR-CSF mean 7.80 +/− 5.07%, HXB2 mean 6.32 +/− 1.65%, [Figure 5](#viruses-06-00709-f005){ref-type="fig"}A).

![A representative example of the strategy used to define infected CD4^+^ T cell subsets. A similar gating strategy to that shown in [Figure 1](#viruses-06-00709-f001){ref-type="fig"} was applied for the detection of infected CD4^+^ T cells. CD4^+^ T cells infected with a subtype C CCR5-using Env‑pseudotyped GFP reporter virus (258-E-5) were first gated on (**A**) FSC *vs*. SSC and then (**B**) viable CD3^+^ T cells (as shown in [Figure 1](#viruses-06-00709-f001){ref-type="fig"}). (**C**) HIV-1 infection was determined by CD3/GFP positivity and used to govern the distribution of infection within CD4^+^ T cell subsets. (**D**) CD3^+^CD4^+^GFP^+^ T cells were divided into CD45RO negative and positive cells. (**E**) CD45RO negative cells were divided into naïve (CD45RO^−^CCR7^+^CD27^+^) and effector (EMRA; CD45ROCCR7^+^CD27^−^) CD4^+^ T cells. (**F**) Using CD122 and CD95, CD4^+^ T cells in the naïve T cell gate were divided into TSCM cells (CD45RO^−^CCR7^+^CD27^+^CD122^+^CD95^+^) (**G**) CD45RO positive cells were divided into memory CD4^+^ T cell subsets; TM (CD45RO^+^CCR7^−^CD27^+^), CM (CD45RO^+^CCR7^+^CD27^+^) and EM (CD45RO^+^CCR7^−^CD27^−^). TSCM were identified using methods similar to those described previously \[[@B11-viruses-06-00709]\]. Percentages represent the percent of the parent population gated.](viruses-06-00709-g004){#viruses-06-00709-f004}

![Infection of CD4^+^ T cell subsets by CCR5- and CXCR4-using viruses. CD4^+^ T cells were isolated from five donors and infected with JR-CSF (CCR5-using) or HXB2 (CXCR4-using) Env-pseudotyped GFP reporter viruses. Over 1 million events were collected on a LSR Fortessa flow cytometer 3 days post infection. (**A**) JR-CSF preferentially infected memory CD4^+^ T cells including CM, TM and EM. In contrast, HXB2 preferentially infected naïve T cells. Both viruses were able to infect TSCM. (**B**) Removal of JR-CSF infected TSCM (CD3^+^CD4^+^CD45RO^−^CD27^+^CCR7^+^CD122^+^CD95^+^) from the infected naïve T cell gate (CD3^+^CD4^+^CD45RO^−^CD27^+^CCR7^+^, as TSCM share the markers CD45RO^−^CD27^+^CCR7^+^ with naïve T cells) revealed a low level of infection of naïve T cells by JR-CSF, whereas HXB2 maintained a relatively high level of infection of naïve T cells. Percentages represent the percentage of naïve T cells infected by each virus, which are TSCM. Bar graphs represent the median and range.](viruses-06-00709-g005){#viruses-06-00709-f005}

The preferential infection of memory T cell subsets by the CCR5-using JR-CSF could be facilitated by high expression of the co-receptor CCR5 on these subsets \[[@B21-viruses-06-00709],[@B27-viruses-06-00709],[@B28-viruses-06-00709],[@B29-viruses-06-00709]\]. Similarly, the preferential infection of naïve T cells by the CXCR4-using HXB2 may have been facilitated by naïve T cells expressing higher levels of CXCR4 \[[@B27-viruses-06-00709],[@B28-viruses-06-00709]\]. Both JR-CSF and HXB2 infected a similar proportion of TSCM cells, approximately 6%--7%; this level of infectivity by the CCR5-using JR-CSF could be contributed to by TSCM expressing a low level of CCR5 compared to other memory T cell subsets (reported above). It is perhaps not surprising that the CXCR4-using HXB2 infected a proportion of TSCM, as this virus can infect other memory CD4^+^ T cell subsets.

Investigation into the proportion of infected CD45RO^−^CD27^+^CCR7^+^ T cells which are TSCM (CD45RO^−^CD27^+^CCR7^+^CD95^+^CD122^+^) revealed that the majority of CD45RO^−^CD27^+^CCR7^+^ cells infected by CCR5-using JR-CSF were TSCM (infected mean CD45RO^−^CD27^+^CCR7^+^ 12.00 +/− 5.52%, TSCM 7.80 +/− 5.07%, 62 +/− 16% of CD45RO^−^CD27^+^CCR7^+^ T cells are TSCM, [Figure 5](#viruses-06-00709-f005){ref-type="fig"}B). In contrast, the minority of CD45RO^−^CD27^+^CCR7^+^ T cells infected by CXCR4-using HXB2 were TSCM (infected mean CD45RO^−^CD27^+^CCR7^+^ 5.13 +/− 2.00%, TSCM 6.32 +/− 1.65%, 25 +/− 7% of CD45RO^−^CD27^+^CCR7^+^ T cells are TSCM, [Figure 5](#viruses-06-00709-f005){ref-type="fig"}B). The overall percentages of TSCM infected by JR-CSF and HXB2 were similar; suggesting that it is the number of naïve T cells infected which increases with CXCR4-using viruses compared to CCR5-using viruses.

Infection of TSCM by CCR5- and CXCR4-using viruses *in vitro* has not been previously reported. This finding, combined with the reported potential of TSCM to be a long-lived reservoir for HIV-1 \[[@B12-viruses-06-00709],[@B16-viruses-06-00709]\], is potentially important for the development of therapeutics targeting the HIV-1 reservoir for both CCR5- and CXCR4-using viruses. It is also important knowledge for therapies targeting subtype B HIV-1 strains, as approximately 40%--50% of subtype B viruses undergo a co-receptor switch during progression to advanced stages of infection \[[@B30-viruses-06-00709],[@B31-viruses-06-00709]\], suggesting infection of TSCM could potentially be maintained throughout HIV-1 disease progression.

2.3. Measurement of Infection in CD4^+^ T Cell Subsets by HIV-1 Subtype C Viruses
---------------------------------------------------------------------------------

We next tested the assay system using GFP reporter viruses pseudotyped with CCR5-using HIV-1 Envs isolated from two subjects infected with HIV-1 subtype C (subjects 258 and 1136). These Envs, and the clinical characteristics of the subjects have been described in detail recently \[[@B32-viruses-06-00709],[@B33-viruses-06-00709]\]. The Env clones from subject 258 used here were 258-E-5, 258-E-6, 258-E-20 and 258-E-23, and those from subject 1136 were 1136-E-1, 1136-E-4, 1136-E-11 and 1136-E-12 \[[@B32-viruses-06-00709],[@B33-viruses-06-00709]\]. All of the subtype C Envs exclusively used the CCR5 co-receptor \[[@B21-viruses-06-00709],[@B22-viruses-06-00709]\].

CD4^+^ T cells from five healthy donors were used to determine CD4^+^ T cell subset tropism of these viruses ([Figure 6](#viruses-06-00709-f006){ref-type="fig"}), using the strategy outlined in [Figure 4](#viruses-06-00709-f004){ref-type="fig"}. All HIV-1 subtype C Envs mediated comparable levels of CD4^+^ T cell infection (mean 2.0 ^+^/~−~ 0.7%), similar to levels demonstrated for the HIV-1 subtype B CCR5-using JR-CSF control virus (1.8 ^+^/~−~ 0.8%). All subtype C viruses preferentially infected memory T cell subsets, similar to JR-CSF; CM T cells were preferentially infected (mean 258 Envs 22.23 ^+^/~−~ 7.26%, 1136 Envs 28.30 ^+^/~−~ 10.89%), then TM (mean 258 Envs 17.10 ^+^/~−~ 6.59%, 1136 Envs 20.32 ^+^/~−~ 9.89%) and EM (mean 258 Envs 10.26 ^+^/~−~ 6.18%, 1136 Envs 8.79 ^+^/~−~ 3.22%, [Figure 6](#viruses-06-00709-f006){ref-type="fig"}A--C). Viruses from both subjects 258 and 1136 infected a similar proportion of TSCM (7 and 5% respectively), naïve T cells (16 and 13% respectively) and a lower proportion of EMRA cells (1%, [Figure 6](#viruses-06-00709-f006){ref-type="fig"}D--F).

Infection of the CD4^+^ T cell subsets by the subtype C viruses was similar to the trends shown by JR-CSF, with the highest proportion of cells infected being CM and TM. A similar level of EM, naïve and EMRA T cells were infected. The proportion of CD45RO^−^CD27^+^CCR7^+^ T cells infected which were TSCM cells was lower than the proportion infected by JR-CSF (mean JR-CSF 62 ^+^/~−~ 16.65%, 258 Envs 43.53 ^+^/~−~ 18.40%, 1136 Envs 32.97 ^+^/~−~ 30.94%). This finding could be influenced by a greater variability in TSCM cells infected by the different subtype C viruses (258 Envs 7.02 ^+^/~−~ 4.70%, 1136 Envs 5.28 ^+^/~−~ 5.12%), and perhaps across different subtypes of HIV-1 (JR-CSF mean 7.80 ^+^/~−~ 5.07%). More research into infection of TSCM by different HIV-1 subtypes is required to determine the factors influencing infection of this T cell subset.

![CD4^+^ T cell subset infection by HIV-1 subtype C Env pseudotyped GFP reporter viruses. CD4^+^ T cells from 5 healthy donors were infected with virus pseudotyped with 4 Envs from subject 258 and four from subject 1136, as described in the Experimental section. The percentage of infection for each CD4^+^ T cell subset was determined and quantified by flow cytometry (as shown in [Figure 4](#viruses-06-00709-f004){ref-type="fig"}). These CCR5-using viruses preferentially infected (**B**) TM and (**C**) CM T cells (mean level \>17% infection), with a modest level of infection was seen in (**A**) EM (mean \>8%), (**D**) TSCM (mean \>5%) and (**E**) Naïve T cells (mean \>13%). (**F**) EMRA were rarely infected (mean 1%). Scatter plots represent the median and interquartile range.](viruses-06-00709-g006){#viruses-06-00709-f006}

3. Experimental Section
=======================

3.1. Cells
----------

293T cells, JC53 cells \[[@B34-viruses-06-00709]\] and TZM-bl cells \[[@B35-viruses-06-00709]\] were maintained as described previously \[[@B21-viruses-06-00709]\]. Peripheral blood mononuclear cells (PBMC) were purified from the blood of healthy HIV-1 negative donors by density gradient centrifugation.

3.2. HIV-1 Env Clones
---------------------

All Envs used in this study are expressed from the pSVIII-Env mammalian expression plasmid \[[@B36-viruses-06-00709]\]. For assay validation and as controls for each assay, the well characterized CCR5-using JR-CSF Env and CXCR4-using HXB2 Env were used, as described previously \[[@B21-viruses-06-00709],[@B25-viruses-06-00709],[@B26-viruses-06-00709]\]. The HIV-1 subtype C Envs are derived from plasma of two subjects (subjects 258 and 1136) with chronic subtype C infection \[[@B33-viruses-06-00709]\]. Four independent Envs from each subject were used in this study. The Env clones from subject 258 were 258-E-5, 258-E-6, 258-E-20 and 258-E-23, and those from subject 1136 were 1136-E-1, 1136-E-4, 1136-E-11 and 1136-E-12 \[[@B32-viruses-06-00709],[@B33-viruses-06-00709]\]. These Envs were shown to be specific for the CCR5 co-receptor by phenotypic entry assays \[[@B33-viruses-06-00709]\] and also by the recently developed CoRSeq~V3-C~ co-receptor usage prediction algorithm, that was designed specifically for HIV-1 subtype C Envs \[[@B37-viruses-06-00709]\].

3.3. Production and Quantitation of Env Pseudotyped GFP Reporter Viruses
------------------------------------------------------------------------

Env pseudotyped, GFP reporter viruses were produced as described previously \[[@B21-viruses-06-00709]\]. Briefly, 293T cells were transfected with pNL4-3Env-GFP \[[@B38-viruses-06-00709]\] and pSVIII-Env plasmids using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) at a ratio of 4:1. Supernatants were harvested 48 h later and filtered through 0.45 μm filters. Viruses were concentrated through a 20% (vol/vol) sucrose cushion, and stored at −80 °C. The TCID~50~ of virus stocks was determined by titration in TZM-bl cells, as described previously \[[@B35-viruses-06-00709],[@B39-viruses-06-00709]\].

3.4. Enumeration of HIV-1 Infection in CD4^+^ T Cell Subsets
------------------------------------------------------------

Forty-eight well tissue culture plates were seeded with 500 μL of 4 × 10^6^/mL of purified CD4^+^ T cells (2 × 10^6^ cells in each well) that were isolated from healthy donors using a RosetteSepCD4^+^ T-cell kit \[Stemcell Technologies (Vancouver, BC, Canada), \>95% purity of CD3^+^CD4^+^ T cells in each experiment\]. Cells were suspended in RPMI 1640 medium containing 10% (vol/vol) FCS at all stages of the experiment. CD4^+^ T cells were incubated for 1 hour prior to infection with 3,000 infectious units of CCR5-using Env pseudotyped GFP reporter virus, or 1,250 infectious units of CXCR4-using virus by spinoculation (1,200 × *g* for 2 h) in V-bottom 96-well tissue culture plates. We empirically determined that this virus inoculum was within the linear range of infection for the CCR5- and CXCR4-using viruses used (data not shown).

Cells were then transferred to 48-well tissue culture plates and incubated for 3 days at 37 °C prior to staining with flow cytometry antibodies ([Table 1](#viruses-06-00709-t001){ref-type="table"}). Flow cytometry antibodies were obtained from BD Biosciences (San Jose, CA, USA) with the exception of CD45RO eFlour450, CD122 PerCP-eFlour710 and the fixable viability dye eFlour506 which were from eBiosciences (San Diego, CA, USA). Cells were fixed for three hours in 4% (wt/vol) paraformaldehyde, then washed and resuspended in FACS buffer \[filtered PBS with 2 mM EDTA and 0.5% (wt/vol) BSA\]. We washed and suspended the cells in FACS buffer, as paraformaldehyde can cause changes in the emission of some fluorochromes, particularly APC-Cy7 dyes \[[@B40-viruses-06-00709]\]. OneComp ebeads were used with the flow cytometry antibodies as compensation controls (eBiosciences).

HIV-1 infection was determined by CD3/GFP positivity and used to determine the distribution of infection within CD4^+^ T cell subsets, which were defined as naïve (CD45RO^−^CCR7^+^CD27^+^), TSCM (CD45RO^−^CCR7^+^CD27^+^CD95^+^CD122^+^), effector memory RA (EMRA, CD45RO^−^CCR7^−^CD27^−^), central memory (CM, CD45RO^+^CCR7^+^CD27^+^) effector memory (EM, CD45RO^+^CCR7^−^CD27^−^) and transitional memory (TM, CD45RO^+^CCR7^−^CD27^+^) T cells. This gating strategy allowed EM to be distinguished from TM \[[@B8-viruses-06-00709],[@B21-viruses-06-00709]\] and superior enumeration of T cell subsets, as described previously \[[@B23-viruses-06-00709],[@B24-viruses-06-00709]\]. TSCM were identified using methods similar to those described recently \[[@B11-viruses-06-00709]\].

For these analyses, \>1,000,000 events were collected on a LSR Fortessa flow cytometer (BD Biosciences) and analyzed with Flowlogic software (eBiosciences). The strategy for measuring HIV-1 infection in CD4^+^ T cell subsets is shown in [Figure 1](#viruses-06-00709-f001){ref-type="fig"} and [Figure 4](#viruses-06-00709-f004){ref-type="fig"}, which are representative experiments of uninfected CD4^+^ T cells ([Figure 1](#viruses-06-00709-f001){ref-type="fig"}) and CD4^+^ T cells infected with GFP reporter virus pseudotyped with 258-E-5 Env ([Figure 4](#viruses-06-00709-f004){ref-type="fig"}), respectively.

4. Conclusions
==============

We developed a novel *in vitro* CD4^+^ T cell infection assay to quantify the level and distribution of HIV-1 infection in CD4^+^ T cell subsets including the newly described TSCM subset. This assay was validated with CCR5-using and CXCR4-using viruses, and was able to distinguish distinct patterns of CD4^+^ T cell tropism associated with different co-receptor specificities. We further show that our assay can be used to measure CD4^+^ T cell subset infection by clinical isolates, specifically HIV-1 subtype C strains.

Our assay permits the simultaneous detection and quantification of HIV-1 infection in naïve, EMRA, TSCM, CM, TM, EM CD4^+^ T cell subsets. Investigation of changes in CD4^+^ T cell tropism by viruses isolated from longitudinal cohorts could potentially predict the establishment of viral reservoirs *in vivo*, and changes in cellular tropism that may be important for HIV-1 pathogenesis.
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